Novo Nordisk, type 2 diabetes
Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study
Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study. The drug, Rybelsus, helped reduce the risk of these events,
Wegovy Maker Novo Nordisk Says New Pill Shows 14% Reduction in Heart Attacks, Strokes in Diabetic Patients
The Wegovy maker’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14%, according to a new trial.
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type 2 diabetes. Regulatory filings for Rybelsus expansion expected by 2025.
Novo Nordisk: Oral Semaglutide Reduces Risk Of Cardiovascular Events In Phase 3 Trial
Novo Nordisk A/S (NVO) announced Monday the headline results from the SOUL cardiovascular outcomes trial, which achieved its primary
Oral semaglutide cuts MACE risk by 14% in adults with type 2 diabetes: SOUL trial
According to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will present more detailed data in 2025 and it intends to file for
Oral Semaglutide Cuts MACE Risk in Patients With Type 2 Diabetes
Oral semaglutide is currently approved under the brand name Rybelsus ® as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Based on these findings, Novo Nordisk expects to file for a label expansion.
Novo Nordisk’s Oral Semaglutide Reduces Cardiovascular Risk by 14% in Type 2 Diabetes Patients, SOUL Trial Shows
Novo Nordisk’s SOUL trial has shown that oral semaglutide reduces the risk of major adverse cardiovascular events (MACE) by 14% in adults with
Novo Nordisk's GLP-1 pill reduces cardiovascular events by 14%
Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.
Zacks.com on MSN1h
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
Novo Nordisk NVO announced positive top-line data from a late-stage cardiovascular outcomes study that evaluated its oral ...
Pharmaceutical Technology4h
Novo Nordisk plans label expansion for Rybelsus following Phase III win
The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 ...
Novo Nordisk: Be Cautious About Buying The Dip
Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
FiercePharma1d
Novo plots US, EU approval filings after oral semaglutide shows cardio benefits in certain diabetes patients
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
Medscape4h
Topline: Oral Semaglutide Cuts Cardiovascular Events in T2D
In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...